title: Design of new drugs for the treatment of Alzheimer's disease based on tacrine structure.
abstract: Tacrine was the first drug approved by FDA for the treatment of Alzheimer's disease. However, its use was restricted in function of side effects observed in some patients. Investigations on the structural basis by which tacrine inhibits cholinesterases activity brought new perspectives for the design of more potent analogs with fewer side effects. This review discusses the recent advances on the development of tacrine-structure-based compounds capable to target multiple molecules involved in Alzheimer's disease. Detailed information on strategies of molecular modifications commonly used in medicinal chemistry, such as bioisosterism, hybridization, dimerization and simplification is presented as well.
authors.affiliation: Grupo de Estudos em Quimica Organica e Biologica (GEQOB), Departamento de Quimica, ICEx, Universidade Federal de Minas Gerais, CEP 31270-901, Belo Horizonte, MG, Brazil.
authors.forename: Roney A N
authors.initials: RA
authors.lastname: de Aquino
authors.forename: Luzia V
authors.initials: LV
authors.lastname: Modolo
authors.forename: Rosemeire B
authors.initials: RB
authors.lastname: Alves
authors.forename: Angelo
authors.initials: A
authors.lastname: de Fatima
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D019281:Dimerization; D015195:Drug Design; D006801:Humans; D013619:Tacrine / Q000737:chemistry / Q000627:therapeutic use*
chemical_list: D002800:Cholinesterase Inhibitors; D013619:Tacrine